Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB6644 is a potent and selective small molecule inhibitor of the RUVBL1/RUVBL2 (also known as Pontin/Reptin) AAA+ ATPase complex. RUVBL1 and RUVBL2 are highly conserved proteins that function as molecular chaperones and are integral components of various multi-protein complexes involved in chromatin remodeling, transcriptional regulation, and DNA damage repair. In oncogenic contexts, the RUVBL1/2 complex is often overexpressed and facilitates tumor progression by modulating key signaling pathways. CB6644 works by inhibiting the ATPase activity of the complex, which leads to the suppression of mTORC1 signaling, reduction of PD-L1 expression, and disruption of YTHDF1-mediated oncogenic translation. Preclinical studies have demonstrated that CB6644 can arrest cell proliferation, induce apoptosis, and enhance immune cell infiltration in models of oral squamous cell carcinoma and colorectal cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CB6644.